Patents by Inventor Jeff A. Zablocki

Jeff A. Zablocki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted heterocyclic compounds
    Publication number: 20070004751
    Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.
    Type: Application
    Filed: September 7, 2006
    Publication date: January 4, 2007
    Inventors: Elfatih Elzein, Dmitry Koltun, Jeff Zablocki
  • Partial and full agonists of A1 adenosine receptors
    Patent number: 7157440
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: January 2, 2007
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfatih Elzein, Prabha Ibrahim, Venkata Palle, Vaibhav Varkhedkar, Jeff Zablocki
  • Prodrugs of A2B adenosine receptor antagonists
    Publication number: 20060293283
    Abstract: Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states.
    Type: Application
    Filed: June 14, 2006
    Publication date: December 28, 2006
    Inventors: Rao Kalla, Dmitry Koltun, Jeff Zablocki, Elfatih Elzein
  • Partial and full agonists of A1 adenosine receptors
    Publication number: 20060287275
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.
    Type: Application
    Filed: August 24, 2006
    Publication date: December 21, 2006
    Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofen Li, Christopher Morrison, Thao Perry, Dengming Xiao
  • A2B adenosine receptor antagonists
    Publication number: 20060281921
    Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.
    Type: Application
    Filed: August 22, 2006
    Publication date: December 14, 2006
    Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
  • A1 adenosine receptor agonists
    Publication number: 20060281705
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Application
    Filed: May 19, 2006
    Publication date: December 14, 2006
    Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
  • A1 adenosine receptor agonists
    Publication number: 20060276428
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists having the structure of Formula I: which are useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Application
    Filed: May 19, 2006
    Publication date: December 7, 2006
    Inventors: Elfatih Elzein, Rao Kalla, Thao Perry, Jeff Zablocki, Xiaofen Li
  • Partial and full agonists of A adenosine receptors
    Patent number: 7144871
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: December 5, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Prabha Ibrahim, Elfatih Elzein, Kevin Shenk, Robert Jiang, Jeff Zablocki, Xiaofen Li, Christopher Morrison, Thao Perry, Dengming Xiao
  • N-pyrazole Areceptor agonists
    Patent number: 7144872
    Abstract: This specification discloses 2-adenosine N-pyrazole compounds having the following formula: and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
    Type: Grant
    Filed: October 18, 2005
    Date of Patent: December 5, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata Palle, Luiz Belardinelli
  • Substituted heterocyclic compounds
    Patent number: 7125876
    Abstract: Disclosed are novel heterocyclic compounds having the structure which are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useflul in the treatment of diabetes.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: October 24, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfatih Elzein, Dmitry Koltun, Jeff Zablocki
  • Aadenosine receptor antagonists
    Patent number: 7125993
    Abstract: Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, having the structure of Formula I or Formula II: by cyclizing a compound of the formula (3):
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: October 24, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfatih Elzein, Rao Kalla, Tim Marquart, Jeff Zablocki, Xiaofen Li
  • Purine inhibitors of cyclin dependent kinase 2 and I?B-?
    Patent number: 7109330
    Abstract: Compounds of the following formula are provided: In the Formula (I), R1 is —X—R1?; in which R1? is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, and X is —NH—. R2 is lower alkyl optionally substituted with one, two or three groups chosen from hydroxy, lower alkoxy, and halogen. And R3 is —NR4R5; in which R4 is hydrogen and R5 is lower alkyl substituted with amino; or (ii) R4 and R5 are both lower alkyl optionally substituted with one, two or three groups chosen from hydroxy and amino. It is to be understood that R1? is not cyclohexylmethyl, phenyl, substituted phenyl, benzyl, phenylethyl, or m-hydroxybenzyl. The compounds inhibit CDK-2 activity and are useful for treating disorders characterized by undesirable cell proliferation.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: September 19, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Robert Lum, Cheri Lynn Blum, Richard Mackman, Michael Wick, Steven Schow, Jeff Zablocki, Prabha Ibrahim
  • C-pyrazole Areceptor agonists
    Patent number: 7109180
    Abstract: 2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: September 19, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle
  • Aadenosine receptor antagonists
    Patent number: 7105665
    Abstract: Disclosed are methods for making novel A2B adenosine receptor antagonists having the structure of formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
    Type: Grant
    Filed: September 23, 2004
    Date of Patent: September 12, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki
  • Partial and full agonists of A1 adenosine receptors
    Publication number: 20060135467
    Abstract: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular the supraventricular tachycardias, emesis, angina, myocardial infarction and hyperlipidemia.
    Type: Application
    Filed: February 15, 2006
    Publication date: June 22, 2006
    Inventors: Jeff Zablocki, Venkata Palle, Elfatih Elzein, Xiaofen Li
  • Substituted heterocyclic compounds
    Patent number: 7056924
    Abstract: Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: June 6, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Prabha Ibrahim, Kevin Shenk, Elfatih Elzein, Venkata Palle, Jeff Zablocki, Kenneth S. Rehder
  • Substituted heterocyclic compounds
    Patent number: 7026321
    Abstract: Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: April 11, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Robert Jiang, Tim Marquart, Jeff Zablocki, Elfatih Elzein, Venkata Palle, Prabha Ibrahim
  • Partial and full agonists of A1 adenosine receptors
    Patent number: 7022681
    Abstract: Disclosed are A1 adenosine receptor agonists of the formula: wherein: R1 is optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; R2 is hydrogen, halo, trifluoromethyl, or cyano; R3 is hydrogen, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted heterocyclyl, R4 and R5 are independently hydrogen or optionally substituted acyl; X is a covalent bond or lower alkylene optionally substituted by cycloalkyl; X1 is a covalent bond or alkylene; Y is a covalent bond or lower alkylene optionally substituted by hedroxy or cycloalkyl; and Z is —C?C—, —R6C?CR7—, or —CHR6CHR7—, in which R6 and R7 at each occurrence are hydrogen or lower alkyl.
    Type: Grant
    Filed: August 15, 2003
    Date of Patent: April 4, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Venkata Palle, Elfatih Elzein, Xiaofen Li
  • A1 adenosine receptor antagonists
    Patent number: 7022710
    Abstract: Disclosed are novel methods of antagonizing the A1 adenosine receptor in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula: wherein R1 is optionally substituted C1-14 alkyl; Y is C1-14 alkylene; and Z is phenyl that is optionally substituted with halo, hydroxy, amino, cyano, or optionally substituted C1-4 alkyl or a pharmaceutically acceptable salt, ester, or prodrug thereof. The A1 adenosine receptors are antagonized in order to treat a disease state is chosen from renal failure, renal dysfunction, nephritis, hypertension, edema, Alzheimers disease, stress, depression, cardiac arrhythmia, restoration of cardiac function, congestive heart failure, diabetes, asthma, respiratory disorders, ischemia-induced injury of the brain, heart and kidney, and diarrhea.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: April 4, 2006
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Rao Kalla, Dewan Zeng
  • Partial and full agonists of A1 adenosine receptors
    Publication number: 20060052330
    Abstract: Disclosed are syntheses suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
    Type: Application
    Filed: August 29, 2005
    Publication date: March 9, 2006
    Inventors: Jeff Zablocki, Elfatih Elzein, Michael Organ, Yaroslav Bilokin, Stanislas Mayer, Anthony Disanti, Scott Miller, Peter Kernast